Breaking News: Large Study Shows Measuring Medication Risk with MedWise® Can Help Reduce Premature Death
Click to learn what these findings mean for medication safety and practice

Research Projects

Outcome-related projects

  • A critical appraisal of drug-drug interaction databases
  • A prospective multicenter cohort study evaluating the characteristics and clinical implications of a clinical decision support system and of pharmacogenomic information relevant to polypharmacy actions in patients with advanced illness who are receiving multiple drugs for pain or other diseases
  • An observational exploration of various medication risk scores as a predictive value of adverse drug event: Development and validation of a dose-sensitive anticholinergic and sedative composite risk scores
  • An observational exploration of various medication risk scores calculated from electronic health record data in a general population and correlated with medical outcomes
  • An observational study of drug-drug interactions involving CYP2D6 among chronic opioid users and their potential impact on healthcare costs
  • Assessment of medication prescribing and adherence in older adults with asthma and chronic obstructive pulmonary disease
  • Comprehensive Medication Review completion rates in medically underserved areas and populations
  • Evaluating patient no-show rates during a pandemic
  • Evaluating the impact of COVID-19 on pharmacist medication errors in a community pharmacy setting
  • Evaluating the impact of CYP2D6 guided opioid therapy on pain management in a Program of All-Inclusive Care for the Elderly (PACE) setting
  • Human on a chip evaluation of drug-drug interactions associated with COVID-19 therapeutics for an at-risk population
  • Identifying the effects of drug pricing and cost barriers on medication adherence
  • Impact of medication management provided via telehealth on the quadruple aim of healthcare
  • Impact of medication safety interventions in a complex elderly population
  • Impact of nutrition and the microbiota on medication effectiveness
  • Impact of pharmacist-driven Medication Safety Reviews™ and polypharmacy calls in the Program of All-Inclusive Care for the Elderly (PACE) setting
  • Investigating changes to Medicaid telehealth reimbursement policies during a pandemic
  • Investigating pharmacy technician perspective of an enhanced medication reconciliation protocol in a national Medication Therapy Management call center setting
  • Investigating the impact of COVID-19 on prescription fills
  • Investigating the impact of SARS-CoV-2 on pharmacy personnel and sleep quality
  • Medication-related problems in an EMTM program
  • Predictive value of MedWise Risk Score™ and pharmacogenomics on health outcomes in patients with type 2 diabetes
  • The clinical effectiveness of pharmacist-driven medication reviews in EMTM
  • Use of telehealth and telepharmacy in the face of the COVID-19 pandemic

Product-related projects

  • Assessing the potential value of preemptive pharmacogenetic testing in a PACE setting
  • Assessment of clinical outcomes following a pharmacist-delivered
  • Assessment of mortality rates in SARS-CoV-2 infected populations treated with repurposed medications
  • Assessment of SOAP notes to characterize the impact of pharmacist’s interventions with a Comprehensive Medication Review
  • Comprehensive Medication Review for patients with type 2 diabetes and dyslipidemia
  • Evaluating community pharmacy staff perception of a clinical decision support system
  • Evaluating medication risk management program outcomes and efficiencies
  • Evaluating the impact of novel medication adherence interventions on the proportion of days covered rate
  • Evaluating the impact of pharmacist-delivered Comprehensive Medication Reviews on National Quality Forum and consumer assessment of healthcare providers and systems scores in a hospice setting
  • Exploration of PACE value
  • Exploring the impact of MedWise service integration on readmission rates within the Discharge Companion Program
  • Identifying and reducing the risks associated with chronic opioid use among older Medicare adults
  • Impact of low level chronic systemic inflammation on Alzheimer’s drug disposition and action
  • Implementation of a pharmacist-driven antipsychotic deprescribing initiative in the Program of All-Inclusive Care for the Elderly (PACE) setting: A pilot study
  • PACE organization attributes associated with economic and clinical outcomes
  • Pharmacometrics modeling and simulation of probe drug profiles subjected to competitive inhibition under various drug administration conditions
  • Reduction in anticholinergic burden related to bladder antimuscarinics for patients in a Program of All-Inclusive Care for the Elderly (PACE) setting
  • Torsadogenic risk evaluation of physiological and supraphysiological medication dosing